215 related articles for article (PubMed ID: 14721774)
1. Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo.
Abdallah M; Abdel-Naser MB; Moussa MH; Assaf C; Orfanos CE
Eur J Dermatol; 2003; 13(6):548-52. PubMed ID: 14721774
[TBL] [Abstract][Full Text] [Related]
2. Treatment of localized vitiligo by autologous minigrafting.
Falabella R
Arch Dermatol; 1988 Nov; 124(11):1649-55. PubMed ID: 3052304
[TBL] [Abstract][Full Text] [Related]
3. An immunohistological study of cutaneous lymphocytes in vitiligo.
Badri AM; Todd PM; Garioch JJ; Gudgeon JE; Stewart DG; Goudie RB
J Pathol; 1993 Jun; 170(2):149-55. PubMed ID: 8345407
[TBL] [Abstract][Full Text] [Related]
4. Reduction of skin-homing cytotoxic T cells (CD8+ -CLA+) in patients with vitiligo.
Antelo DP; Filgueira AL; Cunha JM
Photodermatol Photoimmunol Photomed; 2011 Feb; 27(1):40-4. PubMed ID: 21198882
[TBL] [Abstract][Full Text] [Related]
5. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.
van Geel NA; Mollet IG; De Schepper S; Tjin EP; Vermaelen K; Clark RA; Kupper TS; Luiten RM; Lambert J
Pigment Cell Melanoma Res; 2010 Jun; 23(3):375-84. PubMed ID: 20370855
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo.
De Francesco V; Stinco G; Laspina S; Parlangeli ME; Mariuzzi L; Patrone P
Eur J Dermatol; 2008; 18(3):292-6. PubMed ID: 18474458
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical studies from vitiligo--comparison between active and inactive lesions.
Ahn SK; Choi EH; Lee SH; Won JH; Hann SK; Park YK
Yonsei Med J; 1994 Dec; 35(4):404-10. PubMed ID: 7871844
[TBL] [Abstract][Full Text] [Related]
8. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study.
Anbar TS; El-Sawy AE; Attia SK; Barakat MT; Moftah NH; El-Ammawy TS; Abdel-Rahman AT; El-Tonsy MH
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):17-25. PubMed ID: 22211999
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
[TBL] [Abstract][Full Text] [Related]
10. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation.
Falabella R; Arrunategui A; Barona MI; Alzate A
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 1):228-32. PubMed ID: 7829707
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin?
Prignano F; Betts CM; Lotti T
J Electron Microsc (Tokyo); 2008 Jan; 57(1):25-31. PubMed ID: 18174263
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin.
Prignano F; Pescitelli L; Becatti M; Di Gennaro P; Fiorillo C; Taddei N; Lotti T
J Dermatol Sci; 2009 Jun; 54(3):157-67. PubMed ID: 19282153
[TBL] [Abstract][Full Text] [Related]
13. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
Steitz J; Wenzel J; Gaffal E; Tüting T
Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo vs. hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis).
El-Darouti MA; Marzouk SA; Azzam O; Fawzi MM; Abdel-Halim MR; Zayed AA; Leheta TM
Eur J Dermatol; 2006; 16(1):17-22. PubMed ID: 16436337
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo.
van Geel N; Ongenae K; De Mil M; Haeghen YV; Vervaet C; Naeyaert JM
Arch Dermatol; 2004 Oct; 140(10):1203-8. PubMed ID: 15492182
[TBL] [Abstract][Full Text] [Related]
16. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1.
Watabe D; Kanno H; Yoshida A; Kurose A; Akasaka T; Sawai T
Br J Dermatol; 2007 Aug; 157(2):259-65. PubMed ID: 17596165
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term effects of acetylsalicylic acid treatment on the proliferation and lipid peroxidation of skin cultured melanocytes of active vitiligo.
Zailaie MZ
Saudi Med J; 2004 Nov; 25(11):1656-63. PubMed ID: 15573197
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of aberrant Notch-1 signaling in vitiligo: an implication for pathogenesis.
Seleit I; Bakry OA; Abdou AG; Dawoud NM
Ann Diagn Pathol; 2014 Jun; 18(3):117-24. PubMed ID: 24560443
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic mechanisms of vitiligo in a patient with Sézary syndrome.
Knol AC; Quéreux G; Marques-Briand S; Pandolfino MC; Khammari A; Guilloux Y; Dreno B
Br J Dermatol; 2005 Dec; 153(6):1207-12. PubMed ID: 16307660
[TBL] [Abstract][Full Text] [Related]
20. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
